Type2 Diabetes
Conditions
Brief summary
The aim of this study is to investigate the effects of antagonising GIP after a meal on plasma levels of glucagon. 10 participants are going through four experimental days each, where they ingest a meal and afterwards receive infusions of either GIP receptor antagonist, GLP-1, GIP receptor antagonist + GLP-1 or placebo (saline) in a randomised order. The primary endpoint of the study is plasma levels of glucagon, which we hypothesize will decrease with infusion of GIP receptor antagonist and/or with infusion of GLP-1.
Interventions
OTHERGIP(3-30)NH2
Peptide derived from the naturally occuring gut hormone GIP
Intravenous access for infusions
OTHERGLP-1
Peptide infusion
Sponsors
University Hospital, Gentofte, Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Caucasians between 18-75 years with diet og Metformin treated type 2-diabetes * HbA1c \< 75 mmol/mol * BMI \> 27 kg/m2 * Stable weight (+/- 5%) during the last 3 months
Exclusion criteria
* Treatment with medicine or dietary supplements that cannot the paused for 12 hours * More than 14 units of alcohol weekly or abuse of drugs * Liver disease, estimated at plasma ALAT levels \> 3 x normal value or INR outside normal range * Reduced kidney function (estimated at eGFR \< 60 ml/min/1,73 m2) * Severe arteriosclerotic heart disease or heart failure (NYHA III or IV) * Low red blood cell count (hemoglobin \< 8.3 mmol/l * Special diet or planned weight change during the trial period * Any disease/condition, which the clinical investigators assess will disturb the participation in the clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucagon | 8 weeks - 6 months | Plasma levels of glucagon after a meal in patients with type 2-diabetes |
Countries
Denmark
Outcome results
None listed